A standard approach for treating aggressive prostate cancer is to give therapies that block testosterone, a tumor-stimulating hormone. Should initial hormonal therapies fail, doctors can switch to other drugs that suppress testosterone in different ways. One of them, a drug called abiraterone, has been shown to significantly extend lifespans in men who have become resistant to other hormonal treatments.
But in June, two major studies reported simultaneously that abiraterone also prolongs life in men with aggressive prostate cancer that’s been newly diagnosed. One of the studies, a phase 3 clin Harvard Health...
ما را در سایت Harvard Health دنبال می کنید
برچسب : نویسنده : harvard بازدید : 168 تاريخ : شنبه 28 مرداد 1396 ساعت: 22:12